Quick Answer
Lineage Cell Therapeutics, Inc. reported Operating Income of -$36.62 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$36.62M | -70.5% |
| 2024 | -$21.48M | +13.2% |
| 2023 | -$24.73M | -9.8% |
| 2022 | -$22.52M | +54.2% |
| 2021 | -$49.21M | -86.1% |
| 2020 | -$26.45M | +32.0% |
| 2019 | -$38.88M | +7.0% |
| 2018 | -$41.80M | -7.4% |
| 2017 | -$38.90M | +34.0% |
| 2016 | -$58.97M | +10.4% |
| 2015 | -$65.81M | -29.8% |
| 2014 | -$50.68M | +9.5% |
| 2013 | -$55.99M | -123.9% |
| 2012 | -$25.00M | -33.8% |
| 2011 | -$18.69M | -89.7% |
| 2010 | -$9.85M | -179.9% |
| 2009 | -$3.52M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.79M | +1.4% | +80.9% |
| June 30, 2025 | -$19.78M | -237.1% | -204.1% |
| March 31, 2025 | -$6.50M | +2.3% | -69.4% |
| September 30, 2024 | -$3.84M | +42.7% | +34.5% |
| June 30, 2024 | -$5.87M | -16.8% | +11.9% |
| March 31, 2024 | -$6.66M | -0.3% | +0.7% |
| September 30, 2023 | -$6.71M | -27.7% | -33.5% |
| June 30, 2023 | -$5.02M | -18.7% | +24.4% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -70.5% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Lineage Cell Therapeutics, Inc.’s operating income has declined by 940.2% (from -$3.52 million to -$36.62 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: